Vinflunine for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract

  • Technology appraisal guidance
  • TA272
  • Published: 
Download guidance (PDF)

7 Sources of evidence considered by the Committee

The Evidence Review Group (ERG) report for this appraisal was prepared by Southampton Technology Assessments Centre:

  • Cooper K, Frampton G, Mendes D, Bryant J, Vinflunine for the second line treatment of transitional cell carcinoma of the urothelial tract, September 2010

The following organisations accepted the invitation to participate in this appraisal as consultees and commentators. They were invited to comment on the draft scope, the ERG report and the appraisal consultation document (ACD). Manufacturers or sponsors were also invited to make written submissions. Professional or specialist and patient or carer groups, and other consultees, had the opportunity to give their expert views. Manufacturers or sponsors, professional or specialist and patient or carer groups, and other consultees, also have the opportunity to appeal against the final appraisal determination.

Manufacturers or sponsors:

  • Pierre Fabre

Professional or specialist and patient or carer groups:

  • Macmillan Cancer Support

  • British Uro-oncology Group (BUG)

  • Royal College of Nursing

  • Royal College of Pathologists

  • Royal College of Physicians, Medical Oncology Joint Special Committee

  • United Kingdom Oncology Nursing Society

Other consultees:

  • NHS Bury

  • Department of Health

  • NHS Norfolk

  • Welsh Assembly Government

Commentator organisations (did not provide written evidence and without the right of appeal):

  • British National Formulary

  • Commissioning Support Appraisals Service

  • Department of Health, Social Services and Public Safety for Northern Ireland

  • NHS Quality Improvement Scotland

  • Institute of Cancer Research

  • Southampton Health Technology Assessment Centre

  • National Institute for Health Research Health Technology Assessment Programme

The following individuals were selected from clinical specialist nominations from the non-manufacturer consultees and commentators. They gave their expert personal view on vinflunine by attending the initial Committee discussion and providing written evidence to the Committee. They were also invited to comment on the ACD.

  • Dr Alison Birtle, Consultant Clinical Oncologist, Royal Preston Hospital, nominated by British Uro-oncology Group – clinical specialist

  • Dr John Chester, Honorary Consultant in Medical Oncology, Leeds Institute of Molecular Medicine, nominated by Royal College of Physicians – clinical specialist

  • Dr Tony Elliott, Consultant Clinical Oncologist, The Christie Hospital, nominated by Royal College of Physicians – clinical specialist

Representatives from the following manufacturer attended Committee meetings. They contributed only when asked by the Committee chair to clarify specific issues and comment on factual accuracy.

  • Pierre Fabre

ISBN: 978-1-4731-6731-5